Compare BioNano Genomics Inc (BNGO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs BlackRock TCP Capital Corp — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: BlackRock TCP Capital Corp is far larger — about 24× BioNano Genomics Inc's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | TCPC | |
|---|---|---|
Market Cap | $13.66M | $327.64M |
Sector | Health | Financials |
52-Week High | $4.92 | $7.26 |
52-Week Low | $1.06 | $3.13 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
